Skip to main navigation
Skip to search
Skip to main content
Utrecht University Home
Help & FAQ
Link opens in a new tab
Search content at Utrecht University
Home
People
Research units
Research output
Activities
In the media
Prizes & Grants
Anti-platelet therapy in (cardio)vascular disease
C. M. Hackeng
*
, J. M. Ten Berg
,
V. H.M. Deneer
, H. J.T. Ruven
, J. W. Van Werkum
*
Corresponding author for this work
Pharmacoepi & Clinical Pharmacology
Pharmacoepidemiology and Clinical Pharmacology
St. Antonius Ziekenhuis
St. Antonius Center for Platelet Function Research
Research output
:
Contribution to journal
›
Article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Anti-platelet therapy in (cardio)vascular disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cardiovascular Disease
100%
Clopidogrel
100%
Antiplatelet Therapy
100%
Aspirin
42%
Platelet Function
42%
Active Metabolite
28%
Pharmacological Response
28%
P2Y12 Receptor
28%
Clopidogrel Response
28%
Clinical Trials
14%
Adverse Outcomes
14%
P-glycoprotein (P-gp)
14%
Prodrug
14%
Intestine
14%
Single nucleotide Polymorphism
14%
Non-response
14%
Platelet Inhibition
14%
Dual Antiplatelet Therapy
14%
CYP2C19
14%
Atherosclerotic Cardiovascular Disease (ASCVD)
14%
Low Response
14%
Patient Outcomes
14%
Take-all
14%
Patient Management
14%
Stent Thrombosis
14%
Platelet Activation
14%
Bleeding Complications
14%
Antiplatelet Activity
14%
Long-term Management
14%
Patients with Coronary Artery Disease
14%
Peripheral Arterial Disease
14%
Clopidogrel Therapy
14%
Aspirin Therapy
14%
Incremental Benefits
14%
Cerebral Artery Disease
14%
2-oxo-clopidogrel
14%
Platelet Response
14%
P2Y12 Receptor Antagonist
14%
Popular
14%
Large Degree
14%
Adverse Clinical Outcomes
14%
Pharmacology, Toxicology and Pharmaceutical Science
Clopidogrel
100%
Antiplatelet
100%
Cardiovascular Disease
100%
Acetylsalicylic Acid
36%
Purinergic P2Y12 Receptor
27%
Adenosine Diphosphate
27%
Active Metabolite
18%
Clinical Trial
9%
P-Glycoprotein
9%
Prodrug
9%
Normal Human
9%
Peripheral Occlusive Artery Disease
9%
Coronary Artery Atherosclerosis
9%
Anticoagulant Agent
9%
Coronary Artery Disease
9%
Bleeding
9%
Stent Thrombosis
9%
Adverse Outcome
9%
Cerebral Artery Disease
9%
Receptor Antagonist
9%
Neuroscience
Vascular Disease
100%
Clopidogrel
100%
Platelet
100%
Aspirin
36%
Adenosine Diphosphate
27%
Purinergic P2Y12 Receptor
27%
ABC Transporter Subfamily B
9%
Receptor Antagonist
9%
Prodrug
9%
Single-Nucleotide Polymorphism
9%
Antithrombotic
9%
Metabolic Pathway
9%